{
    "clinical_study": {
        "@rank": "58783", 
        "acronym": "BESTFIT-OLE", 
        "arm_group": {
            "arm_group_label": "TNX-102 SL", 
            "arm_group_type": "Experimental", 
            "description": "1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 3, open-label, extension trial designed to evaluate the long-term safety\n      over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of FM.\n      Patients recruited into this trial are those who have successfully completed the\n      double-blind study, TNX-CY-F202 (F202).  Patients will not be made aware of the therapy they\n      received during the double-blind study."
        }, 
        "brief_title": "12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Fibromyalgia", 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will consist of 7 clinic visits, including Screening/Baseline Visit 1 (Day 0,\n      which is anticipated to be the same date as Visit 6 in F202), visits after 1, 3, 6, 9, and\n      12 months of treatment (Visits 2-6), and a Follow-up Visit (Visit 7) scheduled within one\n      month after stopping study drug treatment.\n\n      Primary:\n\n      The primary objective of the study is to evaluate the long-term safety of TNX-102 SL tablets\n      taken daily at bedtime over 12 months in patients with FM who have completed Study\n      TNX-CY-F202\n\n      Secondary:\n\n      The secondary objective is to evaluate the long-term efficacy of TNX-102 SL tablets taken\n      daily at bedtime to control symptoms of FM"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patient met all prior inclusion and exclusion requirements for Study F202\n             originally, and has had no intervening medical conditions, increased suicidal\n             ideation, or requirements for concomitant medications that preclude exposure to\n             TNX-102 SL or enrollment in the extension study.\n\n          2. The patient completed expected dosing in F202 defined as taking study medication up\n             to Week 12, with at least 70% compliance with medication usage (based on responses\n             from daily IVRS calls recorded during the F202 study) and no major protocol\n             violations.\n\n          3. The patient has provided written informed consent to participate in this extension\n             protocol.\n\n        Exclusion Criteria:\n\n        None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015234", 
            "org_study_id": "TNX-CY-F203"
        }, 
        "intervention": {
            "arm_group_label": "TNX-102 SL", 
            "description": "TNX-102 2.8 mg SL taken daily at bedtime.", 
            "intervention_name": "TNX-102 SL", 
            "intervention_type": "Drug", 
            "other_name": [
                "cyclobenzaprine", 
                "TNX-102 sublingual tablets"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Cyclobenzaprine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "TNX-102 SL", 
            "bedtime", 
            "sublingual", 
            "12-month", 
            "long term safety", 
            "long term efficacy", 
            "Fibromyalgia"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80239"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooksville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34601"
                    }, 
                    "name": "16176 Cortez Boulevard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "100 West Gore Street"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frederick", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21702"
                    }, 
                    "name": "71 Thomas Johnson Drive"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Dartmouth", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02747"
                    }, 
                    "name": "370 Faunce Corner Road"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01605"
                    }, 
                    "name": "Clinical Pharmacology Study Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39202"
                    }, 
                    "name": "CRC of Jackson, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "University of Cincinnati College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43212"
                    }, 
                    "name": "1275 Olentangy River Road"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middleburg Heights", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44130"
                    }, 
                    "name": "18660 Bagley Road"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mechanicsburg", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17055"
                    }, 
                    "name": "1001 South Market Street"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29650"
                    }, 
                    "name": "322 Memorial Drive"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "601 Broadway"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia", 
        "overall_official": {
            "affiliation": "Premier Research", 
            "last_name": "Mark J schmal", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class. Adverse events will also be summarized by severity and relationship to study drug. Serious AEs and AEs leading to discontinuation of study drug will also be summarized.  Actual values and changes from extension Baseline for clinical laboratory test results and vital sign measurements will be summarized at endpoint using descriptive statistics (n, mean, SD, median, minimum, and maximum).", 
            "measure": "Safety", 
            "safety_issue": "No", 
            "time_frame": "every 3 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015234"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "24 hour recall pain.  Change from both baselines in NRS assessments of 24 hour recall pain at months 1, 3, 6, 9 and 12.\nWeekly recall pain.  Change from both baselines in NRS assessments of 7 day recall pain at months 1, 3, 6, 9 and 12.\nFibromyalgia Impact Questionnaire (FIQ).  Change from both baselines in FIQ total score at months 1, 3, 6, 9 and 12.\nPatient Global Impression of Change (PGIC).  A responder analysis of PGIC score at Months 1, 3, 6, 9, and 12 where a responder is defined as a score of 1 or 2 on the PGIC\nChange from both baselines in SF-36 scores at Months 1, 3, 6, 9, and 12\nChange from both baselines in the Patient Reported Outcomes Measurement System (PROMIS) for sleep disturbance and fatigue at Months 1, 3, 6, 9 and 12", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "24 hour recall pain at months 1, 3, 6, 9 and 12"
        }, 
        "source": "Tonix Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tonix Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}